SRXH earnings analysis
What we found in SRXH's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The filing reports $3.392 million of revenue and $(0.36) EPS, but the provided extract does not include prior-period or prior-year financial statements, margins, balance-sheet data, cash flow, or segment results. No quantitative outlook or guidance was provided. Management reported effective disclosure controls as of June 30, 2026, while risk factors were unchanged from the December 5, 2025 Annual Report.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Quarterly revenue and EPS reported
- Reported revenue was $3.392 million and EPS was $(0.36) for the quarter. Prior-period and prior-year comparatives were not included in the provided filing extract, so trend magnitude cannot be calculated.
- Disclosure controls assessed effective
- Management stated that disclosure controls and procedures were effective as of June 30, 2026, following evaluation by the CEO and CFO.
- No material control changes identified
- The company stated that no changes during the quarter ended June 30, 2026 materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Risk-factor disclosure unchanged
- The filing states there have been no material changes from the risk factors in the Annual Report filed on December 5, 2025. Accordingly, the current report does not provide an updated ranking or quantification of key business risks.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.36
What they said about what is next.
The provided 10-Q text contains no quantitative revenue, EPS, margin, cash-flow, or capital-spending outlook. No comparison with prior guidance is available.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 14, 2026
- SRx Health Solutions, Inc. reported total net sales of $3.4 million for Q4 2026, reflecting an operational shift away from specialty healthcare to the Consumer Products segment focused on pet nutrition. The company is…
- 10-Q · February 13, 2026
- SRx reported continuing-operations net sales of $2,807,000 for the quarter (previous-year quarter: $0), generating gross profit of $1,054,000 (~37.6% gross margin) but a continuing-operations loss of $8,614,000 (loss…
- 10-K · December 5, 2025
- SRx completed a strategic reset during FY2025: the company discontinued its capital-intensive Canadian specialty healthcare operations (SRx Canada) and is now a much smaller, consumer-products-only business focused on…
- 10-Q · September 30, 2025
- SRx Health Solutions reported a sharp deterioration in operating results for the quarter ended June 30, 2025: revenue fell to $11.447M from $42.670M year-over-year, driving a wider operating loss and a deeper EPS loss.…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing SRXH makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever